# Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

> **NCT00003959** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** ras peptide cancer vaccine
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00003959
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2001-12
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003959, "Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*